JP2014530009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530009A5 JP2014530009A5 JP2014533232A JP2014533232A JP2014530009A5 JP 2014530009 A5 JP2014530009 A5 JP 2014530009A5 JP 2014533232 A JP2014533232 A JP 2014533232A JP 2014533232 A JP2014533232 A JP 2014533232A JP 2014530009 A5 JP2014530009 A5 JP 2014530009A5
- Authority
- JP
- Japan
- Prior art keywords
- proteinaceous
- proteinaceous molecule
- specific binding
- molecule
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims description 13
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 230000009870 specific binding Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161540920P | 2011-09-29 | 2011-09-29 | |
| US61/540,920 | 2011-09-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017173519A Division JP2018046811A (ja) | 2011-09-29 | 2017-09-08 | 異常細胞を標的とする多重特異性結合分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530009A JP2014530009A (ja) | 2014-11-17 |
| JP2014530009A5 true JP2014530009A5 (OSRAM) | 2017-01-19 |
Family
ID=47018432
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533232A Pending JP2014530009A (ja) | 2011-09-29 | 2012-09-26 | 異常細胞を標的とする多重特異性結合分子 |
| JP2017173519A Pending JP2018046811A (ja) | 2011-09-29 | 2017-09-08 | 異常細胞を標的とする多重特異性結合分子 |
| JP2019211793A Pending JP2020058354A (ja) | 2011-09-29 | 2019-11-22 | 異常細胞を標的とする多重特異性結合分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017173519A Pending JP2018046811A (ja) | 2011-09-29 | 2017-09-08 | 異常細胞を標的とする多重特異性結合分子 |
| JP2019211793A Pending JP2020058354A (ja) | 2011-09-29 | 2019-11-22 | 異常細胞を標的とする多重特異性結合分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11098115B2 (OSRAM) |
| EP (2) | EP2760892A1 (OSRAM) |
| JP (3) | JP2014530009A (OSRAM) |
| AU (3) | AU2012316859A1 (OSRAM) |
| CA (1) | CA2850291A1 (OSRAM) |
| WO (1) | WO2013048243A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012091564A2 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
| EP2760892A1 (en) | 2011-09-29 | 2014-08-06 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| US10946104B2 (en) | 2012-01-13 | 2021-03-16 | Apo-Tb.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| WO2014003552A1 (en) * | 2012-06-26 | 2014-01-03 | Apo-T B.V. | Binding molecules targeting pathogens |
| WO2016077720A1 (en) * | 2014-11-14 | 2016-05-19 | Protein One, Llc | Binding agents and uses thereof |
| TWI603980B (zh) * | 2015-09-01 | 2017-11-01 | 免疫功坊股份有限公司 | 用以治療病理性血栓的聯合接合物構型藥物 |
| BR112018014368A2 (pt) * | 2016-01-13 | 2019-02-05 | Compass Therapeutics Llc | polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit |
| EP3802614A1 (en) * | 2018-06-04 | 2021-04-14 | Apo-T B.V. | Methods and means for attracting immune effector cells to tumor cells |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| EP4171620A4 (en) * | 2020-06-26 | 2025-07-02 | Allymab Inc | LINK MODULATOR |
| EP4284835A4 (en) * | 2021-01-29 | 2025-05-28 | Chugai Seiyaku Kabushiki Kaisha | Molecule specifically acting in a tissue where a cell death being observed |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| AU2022233285A1 (en) | 2021-03-09 | 2023-10-19 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
| KR20250089521A (ko) * | 2022-10-14 | 2025-06-18 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 치료제의 표적화된 전달을 위한 조성물 및 방법 |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB601513A (en) | 1946-02-06 | 1948-05-06 | Koray Ltd | Improvements in or relating to coated tissue especially paper and to coating compositions therefor |
| DE321017C (OSRAM) | 1917-05-15 | 1920-05-11 | Aloysius Petrus Van Leuven | |
| US3687370A (en) | 1971-01-18 | 1972-08-29 | Instapak Corp | Liquid mixing and dispensing apparatus |
| NL9001639A (nl) | 1990-07-19 | 1992-02-17 | Amc Amsterdam | Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen. |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| NZ307633A (en) | 1995-05-09 | 2000-01-28 | Kreatech Biotechnology Bv | Methods for the production of platinum-based linkers between labels and bio-organic molecules, for labelling bio-organic molecules, for detecting |
| EP0973785B1 (en) | 1997-04-10 | 2003-12-03 | Kreatech Biotechnology B.V. | Trans-platinum compound, and diagnostic kit |
| JP4287588B2 (ja) | 1997-08-12 | 2009-07-01 | レアト ベー．フェー． | 作用因子の形質転換能力定量 |
| CN1316910A (zh) | 1998-02-19 | 2001-10-10 | 埃克斯西特治疗公司 | 用于调节淋巴细胞活化的组合物及方法 |
| ATE370967T1 (de) * | 1998-10-21 | 2007-09-15 | Altor Bioscience Corp | Polyspezifische bindemoleküle und deren verwendung |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| ES2321485T3 (es) | 2001-03-30 | 2009-06-08 | Leadd B.V. | Proteinas de fusion para tratamiento especifico de cancer y de enfermedades autoinmunes. |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| JP4049297B2 (ja) | 2001-06-11 | 2008-02-20 | 株式会社ルネサステクノロジ | 半導体記憶装置 |
| GB0115841D0 (en) | 2001-06-28 | 2001-08-22 | Medical Res Council | Ligand |
| US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| WO2003002609A2 (en) | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
| WO2003025020A1 (en) * | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
| WO2005063299A2 (en) | 2003-12-24 | 2005-07-14 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US20050059103A1 (en) | 2001-11-09 | 2005-03-17 | Veuskens Jacky Theo Maria | Means and methods for the detection of immunoglobulin capable of binding to mycobacterium antigen |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| FR2837837B1 (fr) | 2002-03-28 | 2006-09-29 | Roussy Inst Gustave | Epitopes peptidiques communs a des antigenes d'une meme famille multigenique |
| AU2003214721A1 (en) | 2002-04-19 | 2003-11-03 | Leadd B.V. | Fragments of apoptin |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US7820166B2 (en) * | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| EP1567553A2 (en) | 2002-12-03 | 2005-08-31 | Avidex Ltd. | Complexes of receptors |
| DK1613750T3 (en) * | 2003-03-19 | 2016-01-18 | Amgen Fremont Inc | ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof |
| EP1629012B1 (en) * | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US8784821B1 (en) * | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
| ES2296423B1 (es) * | 2003-07-31 | 2009-03-16 | Consejo Sup. Investig. Cientificas | Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones. |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US7488793B2 (en) * | 2003-09-22 | 2009-02-10 | Ludwig Institute For Cancer Research | Isolated peptide which binds to HLA-Cw*07 and uses thereof |
| ATE453405T1 (de) | 2003-11-17 | 2010-01-15 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs |
| SI2418220T1 (sl) | 2003-12-10 | 2017-10-30 | E. R. Squibb & Sons, L.L.C. | Interferon alfa protitelesa in njihova uporaba |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| WO2005113595A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| US20100062001A1 (en) | 2004-06-09 | 2010-03-11 | Technion Research & Development | Antibodies for selective apoptosis of cells |
| AU2005291039A1 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd. | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| JP2009515897A (ja) | 2005-11-10 | 2009-04-16 | キュラジェン コーポレイション | Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法 |
| EP1969005A1 (en) | 2005-12-20 | 2008-09-17 | Erasmus University Medical Center Rotterdam | Apoptosis-inducing protein complexes and therapeutic use thereof |
| JP2009521474A (ja) * | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| US20100158927A1 (en) | 2007-03-29 | 2010-06-24 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| CA2682626A1 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| EP2281005B1 (en) | 2008-04-03 | 2013-11-20 | Vib Vzw | Single domain antibodies capable of modulating bace1 activity |
| WO2009131435A1 (en) | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
| JP5723769B2 (ja) | 2008-06-03 | 2015-05-27 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP2352765B1 (en) * | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| CA2747644C (en) | 2008-12-19 | 2023-01-24 | Ablynx N.V. | Method for generation of immunoglobulin sequences |
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| RU2570633C2 (ru) | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| EP2504360B1 (en) * | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| WO2011064664A2 (en) | 2009-11-24 | 2011-06-03 | Chrontech Pharma Ab | T cell receptors specific for immunodominant ctl epitopes of hcv |
| WO2011085473A1 (en) | 2010-01-13 | 2011-07-21 | Linda Penn | Treating cancer with statins and compounds having dipyridamole activity |
| US20120123218A1 (en) | 2010-11-16 | 2012-05-17 | JPWaVe BV | Methods and means for clinical investigations |
| US9821073B2 (en) | 2010-12-27 | 2017-11-21 | Apo-T B.V. | Polypeptide that binds aberrant cells and induces apoptosis |
| WO2012091564A2 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
| EP2760892A1 (en) | 2011-09-29 | 2014-08-06 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| US10946104B2 (en) | 2012-01-13 | 2021-03-16 | Apo-Tb.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| WO2014003552A1 (en) | 2012-06-26 | 2014-01-03 | Apo-T B.V. | Binding molecules targeting pathogens |
-
2012
- 2012-09-26 EP EP12772530.7A patent/EP2760892A1/en not_active Ceased
- 2012-09-26 JP JP2014533232A patent/JP2014530009A/ja active Pending
- 2012-09-26 CA CA2850291A patent/CA2850291A1/en not_active Abandoned
- 2012-09-26 US US14/348,465 patent/US11098115B2/en active Active
- 2012-09-26 AU AU2012316859A patent/AU2012316859A1/en not_active Abandoned
- 2012-09-26 WO PCT/NL2012/050675 patent/WO2013048243A1/en not_active Ceased
- 2012-09-26 EP EP18153459.5A patent/EP3388451A1/en active Pending
-
2017
- 2017-09-08 JP JP2017173519A patent/JP2018046811A/ja active Pending
- 2017-10-17 AU AU2017248425A patent/AU2017248425B2/en active Active
-
2019
- 2019-11-22 JP JP2019211793A patent/JP2020058354A/ja active Pending
-
2020
- 2020-02-07 AU AU2020200888A patent/AU2020200888A1/en not_active Abandoned
-
2021
- 2021-07-19 US US17/379,822 patent/US20210355209A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/955,569 patent/US20250115662A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530009A5 (OSRAM) | ||
| Hirayama et al. | The present status and future prospects of peptide-based cancer vaccines | |
| Yang et al. | Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy | |
| Xie et al. | CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia | |
| JP2020500523A5 (OSRAM) | ||
| JP2018509163A5 (OSRAM) | ||
| JP2020023523A5 (OSRAM) | ||
| JP2017504324A5 (OSRAM) | ||
| IL271817B2 (en) | Bispecific antibodies against PD-1/PD-L1 and their uses | |
| Meidenbauer et al. | High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma | |
| KR20160127130A (ko) | T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car) | |
| Tuccillo et al. | Cancer-associated CD43 glycoforms as target of immunotherapy | |
| US20240321392A1 (en) | Viral Neoepitopes and Uses Thereof | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| JP2015520172A5 (OSRAM) | ||
| Zhu et al. | Single‐domain antibody‐based TCR‐like CAR‐T: a potential cancer therapy | |
| EP4448108A1 (en) | Adoptive cell therapy combination treatment and compositions thereof | |
| Dao et al. | A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A* 02: 01 complex | |
| Bayó et al. | Vaccines for non-viral cancer prevention | |
| CN105504015B (zh) | 一种mhc-i类限制性抗肿瘤ctl表位肽 | |
| Amissah et al. | NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route | |
| Radvanyi | Discovery and immunologic validation of new antigens for therapeutic cancer vaccines | |
| Godet et al. | An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context | |
| Muthukutty et al. | Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities | |
| Zhao et al. | Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma |